Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Progyny (PGNY)
TipRanks (Mon, 11-May 6:00 AM ET)
TipRanks (Fri, 8-May 3:10 PM ET)
TipRanks (Fri, 8-May 1:55 PM ET)
Stoke Therapeutics (STOK) Gets a Buy from Wedbush
TipRanks (Fri, 8-May 8:57 AM ET)
TipRanks (Fri, 8-May 7:50 AM ET)
Seeking Alpha News (Fri, 8-May 2:22 AM ET)
TipRanks (Fri, 8-May 12:06 AM ET)
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Business Wire (Thu, 7-May 4:01 PM ET)
Business Wire (Thu, 30-Apr 4:01 PM ET)
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire (Thu, 16-Apr 4:01 PM ET)
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Stoke Therapeutics trades on the NASDAQ stock market under the symbol STOK.
As of May 13, 2026, STOK stock price declined to $30.80 with 220,724 million shares trading.
STOK has a beta of 0.94, meaning it tends to be less sensitive to market movements. STOK has a correlation of 0.04 to the broad based SPY ETF.
STOK has a market cap of $1.92 billion. This is considered a Small Cap stock.
Last quarter Stoke Therapeutics reported $6 million in Revenue and -$.79 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.02.
In the last 3 years, STOK traded as high as $40.22 and as low as $3.35.
The top ETF exchange traded funds that STOK belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
STOK has outperformed the market in the last year with a return of +218.8%, while the SPY ETF gained +28.6%. However, in the most recent history, STOK shares have underperformed the stock market with its stock returning -3.4% in the last 3 month period and -7.6% for the last 2 week period, while SPY has returned +9.2% and +4.3%, respectively.
STOK support price is $31.52 and resistance is $33.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STOK shares will trade within this expected range on the day.